TCR2 Therapeutics TCRR
$ 1.48
0.0%
Quarterly report 2023-Q1
added 05-11-2023
Country |
USA |
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Dr. Garry Menzel |
Employees in the company |
109 |
Shares |
38.6 M |
Market Cap[1] |
$ 58.1 M |
EBITDA (LTM) |
$ -129 M |
P/E (LTM) |
-0.58 |
P/S (LTM) |
- |
EPS (LTM) |
-3.4 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.